Pharmafile Logo
Pharmafocus logo
Advanced Search

perampanel

Showing 3 posts of 3 posts found.

Eisai image

Eisai: Fycompa decision ‘deeply regrettable’

November 11, 2014
Research and Development, Sales and Marketing Eisai, Fycompa, Germany, epilepsy, gba, perampanel

Eisai has lashed out at a major German health assessment body, calling its stance on first-in-class epilepsy treatment Fycompa ‘deeply …

News

Eisai sepsis drug fails in phase III

January 26, 2011
Research and Development, Sales and Marketing Eisai, eritoran, perampanel, sepsis

A new treatment for severe sepsis could be abandoned entirely after phase III results fell short. Eisai’s eritoran did not …

News

Encouraging data for Eisai epilepsy drug

August 24, 2010
Sales and Marketing Eisai, epilepsy, perampanel, phase III, seizures, study 306

A new phase III study for Eisai’s perampanel (E2007) suggests the first-in-class treatment is effective as an adjunctive treatment of …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026